Back to Directory
Cotadutide
Metabolic & Weight ManagementGLP-1/Glucagon dual agonist for type 2 diabetes and NASH.
Key Benefits
- ✓Weight loss
- ✓Reduces liver fat
- ✓Improves glucose control
- ✓Treats NASH and T2D
- ✓Dual receptor mechanism
Dosing Information
Dosage Range
Under investigation
Frequency
Daily in trials
Typical Duration
Clinical development
Detailed Protocol
Under clinical investigation. Daily subcutaneous injection in trials. Development ongoing.
About Cotadutide
Cotadutide is a dual GLP-1/glucagon receptor agonist being developed for type 2 diabetes, obesity, and NASH. Clinical trials showed weight loss and liver fat reduction.
Research Notes
Phase 2 trials showed weight loss and NASH benefits. Development ongoing. Part of dual agonist class for metabolic diseases.
Potential Side Effects
- •Nausea
- •Vomiting
- •Diarrhea
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.